The poultry healthcare market size was valued at USD 17.38 billion in 2025 and is estimated to grow from USD 18.86 billion in 2026 to reach USD 28.44 billion by 2031, at a CAGR of 8.56% during the forecast period (2026-2031). This report is Segmented by Product Type (Vaccines, Parasiticides, Anti-Infectives, and More), Animal Type (Broilers, Layers, Breeders, and Others), Route of Administration (Oral, Parenteral, and More), Disease Type (Viral Disease, Bacterial Diseases, and More) End Users (Commercial Poultry, and More) and Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Second-order effects center on fermentation expertise and field-trial validation: suppliers that can provide strain-specific data in commercial settings are capturing distribution slots once held by generic antibiotic vendors. Cross-licensing between feed-additive firms and vaccine majors is emerging as a route to bundle gut-health solutions with immunization protocols, smoothing procurement for integrators.
Broilers delivered 63.34% revenue in 2025, reflecting annual placements exceeding 100 billion birds worldwide. Layers follow, but breeders, although fewer in headcount, are racing ahead at an 8.91% CAGR to 2031. Integrators recognize that every 1-point uptick in hatchability lifts downstream broiler volume by millions of chicks, justifying premium vaccination schedules covering Mycoplasma, ILT, and egg-drop syndrome.
Breeder sensitivity to reproductive pathogens was highlighted when a 2024 United States metapneumovirus flare cut hatch rates 15%, costing USD 80 million in lost chicks. The fallout prompted rapid uptake of live-attenuated breeder vaccines and reinforced biosecurity audits at grandparent farms. Integrators now view breeder health as a profit-center rather than a cost line item, directing R&D toward longer-lasting, combined antigens that minimize handlings.
Asia-Pacific is the fastest-advancing region at 9.34% CAGR to 2031, powered by China’s 7.6 billion broiler output and India’s government-funded vaccination initiatives. Indonesia’s 200 million-dose campaign and Vietnam’s transition to commercialized barns are enlarging the poultry healthcare market. Counterfeit threats persist, prompting firms to embed blockchain labels, yet regional scale outweighs compliance complexity.
Europe, the Middle East & Africa, and South America jointly supply the balance of global receipts. European regulation banning prophylactic antibiotics has accelerated probiotic penetration and autogenous vaccine filings, which rose significantly between 2022 and 2025. Brazil’s 6.9 billion-bird slaughter volume underpins vaccination spend to satisfy influenza-free importers. Argentine peso devaluation spurred a capacity hike but uncovered veterinary bottlenecks. Water-scarce GCC states import most poultry yet are investing in biosecure indoor farms, opening niches for high-efficacy vaccines that qualify under Halal ingredient audits.
Global Poultry Healthcare Market Trends and Insights
Rapid Intensification of Commercial Broiler Production in Emerging Economies
China processed 7.6 billion broilers in 2024, and India turned out 5.3 billion birds across the 2024-2025 cycle, compressing grow-out times and heightening pathogen pressure. Higher stocking densities are pushing integrators toward multivalent vaccines and diagnostics that detect respiratory and enteric infections early. Brazil’s 6.9 billion chicken slaughter in 2024 required biosecure upgrades to retain market access to influenza-free importers. Argentina’s 12% capacity hike between 2023 and 2025 strained veterinary networks, exposing coverage gaps that spurred demand for turnkey immunization contracts. Vietnam and Thailand are pivoting to environmentally controlled houses, trimming mortality yet amplifying the economic cost of any outbreak, which reinforces spending on preventive biologics.Expansion of Government-Subsidized Poultry Vaccination Programs
India’s National Animal Disease Control Programme earmarked USD 450 million in 2024 to underwrite avian-influenza and Newcastle-disease vaccines for backyard and semi-commercial flocks. Indonesia followed in 2025 with 200 million Newcastle-disease doses distributed through new cold-chain hubs. The Philippines partnered with Ceva Santé Animale to locate regional freezers that ensure potency in hot climates. African Union pilots with thermostable formulations are cutting reliance on electricity-intensive refrigeration. Subsidies are enlarging the addressable base for manufacturers and embedding routine immunization into national veterinary codes.Supply Shortages of Critical Antigens for Avian-Influenza Vaccines
The 2024-2025 H5N1 episode forced depopulation of 168.62 million U.S. birds by April 2025, yet antigen capacity lagged because egg-based plants need 18 months to scale. A USD 1 billion USDA program launched in February 2025 is funding cell-culture lines that ramp in six months, though full output will not materialize until late 2027. Europe diverted limited doses from Brazil and India during its 2024 outbreak, underscoring trans-regional interdependence. Competition with human pandemic-influenza vaccines for the same substrates exacerbates scarcity, forcing producers into costly culling and shrinking downstream health-product consumption.Other drivers and restraints analyzed in the detailed report include:
- Growth in Demand for Antibiotic-Free “No-ABF” Value Chains
- Acceleration of Digital Flock-Health Monitoring Platforms
- Escalating Counterfeit Biologics Trade in South-East Asia
Segment Analysis
Vaccines retained a 47.12% lion’s share in 2025, anchored by compulsory Newcastle disease, infectious bronchitis, and avian influenza immunizations. Probiotics and prebiotics are charting an 8.79% annual rise to 2031 as large retailers demand antibiotic-free birds and peer-reviewed trials show Bacillus strains cutting Salmonella counts by up to 60%. Anti-infectives are losing ground where regulators curb medically important molecules, while parasiticides sustain volume through shuttle programs that rotate ionophores with vaccines. Diagnostics is a bright spot; IDEXX’s two-hour multiplex PCR for H5, H7, and H9 is gaining traction among integrators seeking rapid flock segregation.Second-order effects center on fermentation expertise and field-trial validation: suppliers that can provide strain-specific data in commercial settings are capturing distribution slots once held by generic antibiotic vendors. Cross-licensing between feed-additive firms and vaccine majors is emerging as a route to bundle gut-health solutions with immunization protocols, smoothing procurement for integrators.
Broilers delivered 63.34% revenue in 2025, reflecting annual placements exceeding 100 billion birds worldwide. Layers follow, but breeders, although fewer in headcount, are racing ahead at an 8.91% CAGR to 2031. Integrators recognize that every 1-point uptick in hatchability lifts downstream broiler volume by millions of chicks, justifying premium vaccination schedules covering Mycoplasma, ILT, and egg-drop syndrome.
Breeder sensitivity to reproductive pathogens was highlighted when a 2024 United States metapneumovirus flare cut hatch rates 15%, costing USD 80 million in lost chicks. The fallout prompted rapid uptake of live-attenuated breeder vaccines and reinforced biosecurity audits at grandparent farms. Integrators now view breeder health as a profit-center rather than a cost line item, directing R&D toward longer-lasting, combined antigens that minimize handlings.
Complete Report Scope:
- By Product Type
- Vaccines
- Parasiticides
- Anti-infectives
- Probiotics & Prebiotics
- Diagnostics Kits & Reagents
- By Animal Type
- Broilers
- Layers
- Breeders
- Others
- By Administration Route
- Oral
- Parenteral
- Topical
- Spray / Aerosol
- By Disease Type
- Viral Disease
- Bacterial Diseases
- Parasitic Diseases
- Fungal Diseases
- By End Users
- Commercial Poultry
- Backyard Poultry
- Veterinary clinic
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America accounted for 39.76% revenue in 2025, supported by the United States’ 9 billion broiler flock and Canada’s export-oriented processors. FDA’s conditional clearance of Zoetis’ H5N1 vaccine in February 2025 lets producers vaccinate rather than depopulate, with potential savings of USD 500 million annually if endemic status emerges. High feed costs and labor scarcity temper the adoption of premium biologics, steering buyers toward solutions with tight payback metrics.Asia-Pacific is the fastest-advancing region at 9.34% CAGR to 2031, powered by China’s 7.6 billion broiler output and India’s government-funded vaccination initiatives. Indonesia’s 200 million-dose campaign and Vietnam’s transition to commercialized barns are enlarging the poultry healthcare market. Counterfeit threats persist, prompting firms to embed blockchain labels, yet regional scale outweighs compliance complexity.
Europe, the Middle East & Africa, and South America jointly supply the balance of global receipts. European regulation banning prophylactic antibiotics has accelerated probiotic penetration and autogenous vaccine filings, which rose significantly between 2022 and 2025. Brazil’s 6.9 billion-bird slaughter volume underpins vaccination spend to satisfy influenza-free importers. Argentine peso devaluation spurred a capacity hike but uncovered veterinary bottlenecks. Water-scarce GCC states import most poultry yet are investing in biosecure indoor farms, opening niches for high-efficacy vaccines that qualify under Halal ingredient audits.
List of Companies Covered in this Report:
- Anicon Laboratories
- Avivagen
- Bimeda
- Biochek
- Boehringer Ingelheim
- Ceva Santé Animale
- Dechra Pharmaceuticals
- Elanco
- Hester Biosciences
- Hipra
- Huvepharma
- IDEXX
- Indovax
- Megacor Diagnostik
- Merck
- Phibro Animal Health
- Provet Pharma
- Thermo Fisher Scientific
- Venky’s India Ltd.
- Virbac
- Zoetis
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anicon Laboratories
- Avivagen
- Bimeda
- Biochek
- Boehringer Ingelheim Vetmedica
- Ceva Santé Animale
- Dechra Pharmaceuticals
- Elanco Animal Health
- Hester Biosciences
- HIPRA
- Huvepharma
- IDEXX Laboratories
- Indovax
- Megacor Diagnostik
- Merck Animal Health
- Phibro Animal Health
- Provet Pharma
- Thermo Fisher Scientific
- Venky’s India Ltd.
- Virbac
- Zoetis Inc.
